Skip to main navigation Skip to search Skip to main content

A phase 3, randomized, placebo-controlled, observer-blinded trial to evaluate the safety of a 6-valent OspA-based lyme disease vaccine (VLA15) in healthy children 5 through 17 years of age

Project: Research

Project Details

StatusFinished
Effective start/end date04/27/23 → 01/31/26

Funding

  • ICON Clinical Research: $251,272.54